EscharEx - MediWound

Drug Profile

EscharEx - MediWound

Alternative Names: EscharEx

Latest Information Update: 17 May 2017

Price : $50

At a glance

  • Originator MediWound
  • Class Enzymes; Skin disorder therapies
  • Mechanism of Action Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Leg ulcer; Wounds

Most Recent Events

  • 09 May 2017 MediWound plans to initiate pivotal trials for Wounds (chronic and hard-to-heal wounds) in USA
  • 31 Jan 2017 Final efficacy data from a phase II trial in Wounds released by MediWound
  • 02 Feb 2016 Top-line efficacy data from a phase II trial in Wounds released by MediWound
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top